Female Sexual Dysfunction

Introduction

Female sexual dysfunction (FSD) affects an estimate 84 million women across the seven major pharmaceutical markets and represents a significant opportunity for investment. Despite its high prevalence, FSD is poorly understood and defined. Currently there is just one product approved for the treatment of FSD; P&G's Intrinsa (testosterone) is marketed in Germany, France and the UK.

Scope

• Comprehensive overview of the FSD pipeline with focus on clinical candidates in development for FSD
• Analysis of the latest clinical trials results of FSD drug candidates in Phase I to III development
• Analysis of the challenges and opportunities facing products in Phase III and above with estimates of launch dates.
• Separation of drugs in development for different patient segments including hypoactive sexual desire disorder and female sexual arousal disorder

Highlights

Despite the relatively large patient population, currently there is just one approved drug treatment for FSD. There is much unmet need among patients and physicians and consequently Datamonitor believes there is an opportunity to develop this market to parallel to that of the multi-billion dollar male erectile dysfunction market

While Intrinsa has benefited from first-to-market advantage, the drug suffers from several weaknesses that can be targeted by pipeline drug companies. Pipeline products can compete on safety, cost, efficiency, delivery, 'cosmetic elegance' and reduced skin irritation

The FDA rejection of Intrinsa for FSD has left a big gap in the market. Depending on the outcome of ongoing clinical trials, there are several appealing inlicensing opportunities for larger companies wishing to unlock the potentially lucrative US market

Reasons to Purchase

• Understand the placement of key compounds within the FSD development pipeline
• Identify challenges to be met and niches to be filled in the FSD market
• Assess novel mechanisms of action in the early pipeline and their potential for the treatment of FSD